0001193125-22-004578.txt : 20220107 0001193125-22-004578.hdr.sgml : 20220107 20220107171553 ACCESSION NUMBER: 0001193125-22-004578 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211231 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220107 DATE AS OF CHANGE: 20220107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 22518939 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 d267523d8k.htm 8-K 8-K
false 0001576280 0001576280 2021-12-31 2021-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 31, 2021

 

 

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38683   45-4139254

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

505 Penobscot Dr.

Redwood City, California 94063

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.00001   GH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events.

On December 31, 2021, Guardant Health, Inc. (the “Company”) entered into a Settlement and License Agreement (the “Settlement Agreement”) with Foundation Medicine, Inc. (“FMI,” now a subsidiary of Roche Holdings, Inc.), consistent with the binding term sheet entered into by the parties on May 13, 2021 and announced in a Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on May 17, 2021. Under the terms of the Settlement Agreement, FMI will pay the Company $25 million as well as future royalties for the remaining term of the licensed patents, while the Company will grant FMI a non-exclusive license to a defined subset of the Company’s patents. As a result of the Settlement Agreement, all pending patent litigation between the parties will be dismissed.

On January 7, 2022, the Company issued a press release announcing the Settlement Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of federal securities laws, such as statements about final court approval of the settlement and entry into a definitive settlement agreement. These statements are based on current expectations and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K include those discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the SEC. The forward-looking statements in this Current Report on Form 8-K are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press release of Guardant Health, Inc., dated January 7, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                   GUARDANT HEALTH, INC.
Date: January 7, 2022        
      By:  

/s/ John G. Saia

        John G. Saia
        Senior Vice President, General
Counsel and Corporate Secretary
 EX-99.1 2 d267523dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation

REDWOOD CITY, Calif. January 7, 2022 – Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Guardant Health $25 million as well as future royalties for the remaining term of the licensed digital sequencing technology patents. In turn, Guardant Health will grant Foundation Medicine a non-exclusive license to a defined subset of its digital sequencing technology patents. As a result of this settlement, all pending patent litigation between Foundation Medicine and Guardant Health will be dismissed.

“We are pleased with the Foundation Medicine settlement agreement as it recognizes the importance of our scientific discoveries and validates the strong intellectual property rights we have built as a company,” said Helmy Eltoukhy, Guardant Health Co-CEO.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press

release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Investor Contact:

Carrie Mendivil

investors@guardanthealth.com

Media Contact:

Michele Rest

press@guardanthealth.com

EX-101.SCH 3 gh-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 gh-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 gh-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g267523g0108023401447.jpg GRAPHIC begin 644 g267523g0108023401447.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HI M"0 23@#J36?)K^CQ2>6^IVBL.H\Y>*:BWLA-I;FC13(9HKB,20RI(AZ,C @_ MB*?2&%%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0 M(2 "2< =32 MUE>)I7@\+ZG)&2'%L^".W&,U48\TDNXI.R;,*)+CQK(I]7\2R:BCL@B<" ?W0IX_P :6)Q+IZ1T1Z6395]>G+GV2U?F]OZ\CU>^ M\.2:,6U+PX6ADC&Z2SS^[F7TQV/I6_I.IPZOID-[!PL@Y4]5/<'Z&JGAC65U M[0;:] P[+MD'HPX-4/"8\F_UZU0_N8KYM@'1<@$BM5/VM/F>Z_(\RI2EAZSI MM6W37FC;U'5;+28/.O;A8D)P,]6/L.]9UMXPT>XG6$S20,YPGGQE WT)JC9P M1ZIXVU*6\ D^Q*D<$;B6R_8M5M9)49=WRP%@!]1TJE3C=1 MLV_(S:3;+<,5B7'WB.:Y MK3KJVO?&%K?L\FG9CR,<;JL>(?^1E\.?]=Y/_ $&E[)*2B^P_:/EOYF]/ M>VUM/!#-*J23L5B4_P 1J+4]5L](MA<7LOEQE@H.">37G>OZK9:GK-[='4$A METW"V2$GYW!RQ_'I6SXCU5=1\+Z5J-O$9M]Q&WEKU)[BM%AK.-^NY'M])6Z' M16'B32=2N/L]M= S8R(V4J2/;-5CXTT%796O"-C%68QM@$=><5B6T\_BO4K& M\@TW[#!83EI)'8;V(&-N!6IX.@AET*3S(D;-S+]Y0?XC2E2A!-N_I?U"-2VTE[)9I*IN(U#NG< ]#7+1/!X>\6:@D1$=B] MG]IDC'1&!Z^V:YBPUNSM=4MO$!OU:[N[ADNK?)^6)N%_+ -$<-S7:VZ Z_+9 M/YGJ#7MNE['9O*JW$BET0]6 ZX_.FWM];Z? )KJ39&6"9QW)P*Y'Q18R:EXP MT>.WN&AF%O-)#(IZ,,$?A4.M:RVI>&VM[J/R=1MKN!;B(_[XPP]C2C03Y7WW M^\,( MXPVAD(N3JL&>.O)KIQ&BC"HH'H!425-032>OG_P"HN;DTWL.I*6DK$U%J&\M MH[VRGM91^[FC:-OH1BIJ*$[:@;: MC\/->M]1>&"T:>(M\DJ="/?TKV'5]!LM95#<*R31\QSQ-M=/H:RQH/B"(>7# MXE17TF*'P)X15+V0/<'+>6IY= MST45H^$].GLM*>:\&+R\E:XF'H6[?@,4W3_"D%O>+?7]U-J-ZOW9)^B?[J]! M704WR0A[.!QU*E2O5=:KN_U,#5=%N_[475](F2*\V;)8Y!\DRCIGWJI<0^*= M7A:SN(;33X'&V66.3>S+W ]*ZJBFJS26BT,W33.;N] N+*>RO-%\L2VL/D>3 M*<+(GU[&JUSI>O:K+]MNEMK>>WC9;6!'+ .W&XM]*ZVBFJTEZ@Z4696E:%9Z M?ID%LT$,CHOSNR EF[G-8DOA:[1Y+>V>,6?VQ+J)2?N?WA7844HUIIM]P=*+ M5C";1[BTU_[?I[*(+D;;J$G )[./>LW3K'Q/I5M):6T5@T9E=UD=SGYCGI77 MT4*M*UFK@Z2O=:'&3>$M0NCOO+N.:>ZE7[6ZC $2G.Q1Z9KH[K1K"ZLI;5K2 M%5D0ID1@$<5H442K3E;R"-.*.6T[0=1AU+1[F[DC?[#!+ [ \L#@*?R%3>)? M"\>MM!MFBBH XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Dec. 31, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001576280
Document Type 8-K
Document Period End Date Dec. 31, 2021
Entity Registrant Name GUARDANT HEALTH, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38683
Entity Tax Identification Number 45-4139254
Entity Address, Address Line One 505 Penobscot Dr.
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94063
City Area Code 855
Local Phone Number 698-8887
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.00001
Trading Symbol GH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d267523d8k_htm.xml IDEA: XBRL DOCUMENT 0001576280 2021-12-31 2021-12-31 false 0001576280 8-K 2021-12-31 GUARDANT HEALTH, INC. DE 001-38683 45-4139254 505 Penobscot Dr. Redwood City CA 94063 855 698-8887 false false false false Common Stock, par value $0.00001 GH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d267523d8k.htm d267523dex991.htm gh-20211231.xsd gh-20211231_lab.xml gh-20211231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d267523d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d267523d8k.htm" ] }, "labelLink": { "local": [ "gh-20211231_lab.xml" ] }, "presentationLink": { "local": [ "gh-20211231_pre.xml" ] }, "schema": { "local": [ "gh-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gh", "nsuri": "http://guardanthealth.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d267523d8k.htm", "contextRef": "duration_2021-12-31_to_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d267523d8k.htm", "contextRef": "duration_2021-12-31_to_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-004578-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-004578-xbrl.zip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end